Shanler Stuart 4
4 · Aclaris Therapeutics, Inc. · Filed Dec 21, 2018
Insider Transaction Report
Form 4
Shanler Stuart
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2018-12-18+1,450→ 269,892 total - Tax Payment
Common Stock
2018-12-18$6.30/sh−412$2,596→ 269,480 total - Exercise/Conversion
Restricted Stock Units
2018-12-18−1,450→ 1,450 total→ Common Stock (1,450 underlying)
Footnotes (3)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- [F3]On December 18, 2015, the reporting person was granted 5,800 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.